ReviewIntensive care medicine1998
Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care.
Review in Intensive care medicine, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 3 syntheses or guidelines pooled it, 279 citations in OpenAlex.
- ICU-acquired candidemia within selective digestive decontamination studies: a meta-analysis.Intensive care medicine · 2015Pooled it
- Single-drug therapy or selective decontamination of the digestive tract as antifungal prophylaxis in critically ill patients: a systematic review.Critical care (London, England) · 2007Pooled it
- Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis.Intensive care medicine · 2005Pooled it
- The atypical antipsychotic aripiprazole alters the outcome of disseminatedInfection and immunity · 2024Article
- The atypical antipsychotic aripiprazole alters the outcome of disseminatedbioRxiv : the preprint server for biology · 2024Article
- Risk of candidiasis associated with interleukin-17 inhibitors: Implications and management.Mycology · 2024Review
- Characterization and susceptibility of non-albicansFrontiers in public health · 2023Observational
- Identification of Inhibitors of Fungal Fatty Acid Biosynthesis.ACS infectious diseases · 2021Article
- One stone, three birds: one AIEgen with three colors for fast differentiation of three pathogens.Chemical science · 2020Article
- A Systematic Screen Reveals a Diverse Collection of Medications That Induce Antifungal Resistance inAntimicrobial agents and chemotherapy · 2019Article
- Pre-clinical Imaging of Invasive Candidiasis Using ImmunoPET/MR.Frontiers in microbiology · 2018Article
- Novel Cell-Killing Mechanisms of Hydroxyurea and the Implication toward Combination Therapy for the Treatment of Fungal Infections.Antimicrobial agents and chemotherapy · 2017Article
- Antimicrobial potential of two traditional herbometallic drugs against certain pathogenic microbial species.BMC complementary and alternative medicine · 2016Article
- Neutrophil Integrins and Matrix Ligands and NET Release.Frontiers in immunology · 2016Review
- Antifungal Susceptibility Patterns of Candida Species Recovered from Endotracheal Tube in an Intensive Care Unit.Advances in medicine · 2016Article
- Invasive Candida infections in patients of a medical intensive care unit: attempt of improving diagnosis by quantifying the colonization.Wiener klinische Wochenschrift · 2015Observational
- Observational
- Candida colonization index and subsequent infection in critically ill surgical patients: 20 years later.Intensive care medicine · 2014Review
- Invasive candidiasis in intensive care unit; consensus statement from an Iranian panel of experts, July 2013.JRSM open · 2014Review
- Bloodstream infections in patients with hematological malignancies: which is more fatal - cancer or resistant pathogens?Therapeutics and clinical risk management · 2014Article
Corrections and comments
- Commented on by
Authors and funding
15 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of systemic Candida infections in patients requiring intensive care has increased substantially in recent years as a result of a combination of factors. More patients with severe underlying disease or immunosuppression from anti-neoplastic or anti-rejection chemotherapy and at risk from fungal infection are now admitted to the ICU. Improvements in supportive medical and surgical care have led to many patients who would previously have died as a result of trauma or disease surviving to receive intensive care. Moreover, some therapeutic interventions used in the ICU, most notably broad-spectrum antibiotics and intravascular catheters, are also associated with increased risks of candidiasis. Systemic Candida infections are associated with a high morbidity and mortality, but remain difficult to diagnose and ICU staff need to be acutely aware of this often insidious pathogen. A number of studies have identified risk factors for systemic Candida infection which may be used to identify those at highest risk. Such patients may be potential candidates for early, presumptive therapy. Here we review the epidemiology, pathogenesis, morbidity and mortality of systemic Candida infections in the ICU setting, and examine predisposing risk factors. Antifungal treatment, including the use of amphotericin B, flucytosine and fluconazole, and the roles of early presumptive therapy and prophylaxis, is also reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.